A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug

NCT01565707 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

189

Enrollment

INDUSTRY

Sponsor class

Conditions

Urinary Bladder, Overactive

Interventions

DRUG: Solifenacin Succinate Suspension
DRUG: Placebo
BEHAVIORAL: Urotherapy

Sponsor

Astellas Pharma Europe B.V.